{
    "nctId": "NCT00245024",
    "briefTitle": "Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer",
    "officialTitle": "Phase IB Sulindac Study for Women at High Risk for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Sulindac and sulindac metabolite levels in nipple aspirate fluid (NAF) after 6 weeks of treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meets 1 of the following criteria:\n\n  * Gail assessment score \\> 1.7% risk for 5 years\n  * History of lobular carcinoma in situ (pathology report required)\n  * History of ductal carcinoma in situ (DCIS) (pathology report required)\n  * History of breast cancer in \u2265 1 first-degree relative or history of BRCA1 or BRCA2 positivity not treated with oophorectomy or mastectomy (test report required)\n  * History of breast cancer in \u2265 2 second-degree relatives\n  * Any family history of breast cancer diagnosed prior to age 50\n  * Personal history of breast cancer (invasive or DCIS) with 1 breast intact\n* Nipple aspirate fluid production \u2265 5 microliters\n* Negative mammogram for breast cancer within the past 10 months\n\n  * Any suspicious breast masses must be examined by a clinical professional\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nSex\n\n* Female\n\nMenopausal status\n\n* Pre- or postmenopausal\n\nPerformance status\n\n* Karnofsky 80-100%\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* WBC \u2265 3,000/mm\\^3\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* No history of bleeding or clotting disorder\n\nHepatic\n\n* Bilirubin \u2264 2.0 mg/dL\n* AST and ALT \u2264 2.0 times upper limit of normal\n* No indication of abnormal liver function\n\nRenal\n\n* Creatinine normal\n\nCardiovascular\n\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n\nGastrointestinal\n\n* No frequent, chronic, or moderate/severe gastric complaint\n* No upper gastrointestinal problems (e.g., symptoms of heartburn, dyspepsia, or abdominal pain) requiring prescription or nonprescription medical remedies more than once per week (on average)\n* No history of peptic ulcer or occult or gross intestinal bleeding\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No history of allergic reaction (e.g., urticaria, asthma, rhinitis) or gastric intolerance attributed to compounds of similar chemical or biological composition to sulindac\n* No history of allergy attributed to lidocaine, EMLA\u00ae cream, or xylocaine\n* No concurrent uncontrolled illness\n* No ongoing or active infection\n* No psychiatric illness or social situation that would preclude study compliance\n* No more than 2-3 servings of alcohol per week during study participation\n\nPRIOR CONCURRENT THERAPY:\n\nChemotherapy\n\n* More than 6 months since prior chemotherapy for breast cancer (invasive or DCIS)\n\nEndocrine therapy\n\n* More than 6 months since prior hormonal therapy for breast cancer (invasive or DCIS)\n* No concurrent hormone-suppressing agents (e.g., tamoxifen or anastrozole)\n* No concurrent selective estrogen-receptor modulators\n* No concurrent aromatase inhibitors\n\nRadiotherapy\n\n* More than 6 months since prior radiotherapy for breast cancer (invasive or DCIS)\n\nSurgery\n\n* See Disease Characteristics\n* No prior breast duct-disrupting surgery (e.g., mastectomy) that would preclude ductoscopy\n\nOther\n\n* More than 3 months since prior warfarin or other systemic anticoagulant\n* More than 4-6 weeks since prior nonsteroidal anti-inflammatory drugs\n* No concurrent phenytoin or sulfonamides\n* No concurrent warfarin or other systemic anticoagulant\n* No other concurrent nonsteroidal anti-inflammatory drugs (including low-dose aspirin)\n* No concurrent large doses of supplements, vitamins (\\> regular daily multivitamin) and/or herbal medicines (e.g., echinacea, ginkgo biloba, Hypericum perforatum \\[St. John's wort\\], or herbal tea)\n* No other concurrent investigational agents",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}